Future Directions: ctDNA Testing and Management of the CRC Patient
October 1st 2025Experts discuss how the evolving landscape of patient access to medical information challenges clinicians to stay current and communicate effectively, while emphasizing the expanding role of circulating tumor DNA testing across multiple cancers—offering more precise, personalized treatment guidance and paving the way for earlier, targeted interventions that improve patient outcomes and quality of life.
ctDNA Monitoring as SOC Surveillance Following CRC Resection: Financial Considerations
October 1st 2025Experts discuss that although financial concerns about ctDNA testing exist, they are generally manageable with patient education and transparent communication, and that incorporating ctDNA into formal clinical guidelines could reduce insurance barriers and alleviate patient anxiety, ultimately enabling broader access to this valuable personalized cancer monitoring tool.
Patient-Perceived Utility of ctDNA Testing and Dimension of Well-Being: Results from BESPOKE CRC
October 1st 2025Experts discuss how real-world data counter concerns that ctDNA testing increases patient anxiety, highlighting that most patients feel more reassured and confident in their care when receiving personalized ctDNA results, which supports its integration into routine surveillance to improve both clinical decision-making and patient quality of life.
ctDNA Monitoring as SOC Surveillance Following CRC Resection: Real-World Applicability
September 24th 2025Experts emphasize that sustained ctDNA negativity beyond 18 to 24 months enables safely extending surveillance intervals, easing patient burden while improving personalized colorectal cancer follow-up despite ongoing challenges with interpretation and insurance coverage.
GALAXY and BESPOKE CRC ctDNA Surveillance Analysis Study Conclusions
September 24th 2025Experts discuss how integrating ctDNA testing into standard colorectal cancer surveillance enhances early recurrence detection, improves eligibility for curative metastasis-directed therapies, and empowers more personalized, timely treatment decisions, ultimately improving both clinical outcomes and patient confidence.
Interpreting the GALAXY and BESPOKE CRC Data: Transient ctDNA Clearance and the Risk of Recurrence
September 10th 2025Experts discuss how ctDNA dynamics after colorectal cancer surgery can guide personalized surveillance and treatment, with recurrent positivity signaling high relapse risk and potential therapy resistance, whereas sustained negativity may support less intensive monitoring, balancing effective oversight with patient quality of life.
The Importance of Multidisciplinary Communication and Care Coordination for the Resected CRC Patient
September 3rd 2025Experts discuss the critical role of clear pathology communication and risk assessment after colorectal cancer surgery, highlighting how surgical quality, pathologic staging, and timely ctDNA testing guide personalized adjuvant therapy decisions and coordinated long-term surveillance to optimize patient outcomes.
Evaluating the Clinical Value of ctDNA Testing in the Longitudinal Management of the CRC Patient
September 3rd 2025Experts discuss the expanding role of ctDNA as a prognostic and predictive tool in colorectal cancer management, emphasizing its ability to personalize postoperative surveillance and treatment decisions—particularly in ambiguous clinical scenarios—while highlighting the need for sensitive assays and thoughtful communication around emotionally challenging results.
Identifying Patients Requiring Intensive Surveillance Following CRC Resection
August 27th 2025Experts discuss how postoperative surveillance after colorectal cancer surgery is increasingly personalized by integrating pathologic staging, surgical quality, and ctDNA testing to adjust monitoring intensity, with higher-risk or uncertain cases receiving more aggressive follow-up to optimize early detection and intervention.
How Postoperative ctDNA Results Influence Treatment Decisions Following CRC Resection
August 27th 2025Experts discuss the pivotal role of ctDNA in postoperative colorectal cancer care, using it alongside pathology and staging to personalize recurrence risk assessment and guide adjuvant therapy decisions, particularly in nuanced cases where ctDNA results and clinical risk factors may not align.
Communicating the Risk of Disease Relapse to the Patient After Curative CRC Resection
August 20th 2025Experts discuss how initial postoperative visits after colorectal cancer surgery integrate pathology review, recurrence risk assessment, and timely ctDNA testing to personalize prognosis and guide surveillance, emphasizing the importance of surgical quality indicators and molecular tools in shaping follow-up care.
The Oncology Surgeon’s Role in Postoperative Surveillance Following CRC Resection
August 20th 2025Experts discuss how postsurgical surveillance for colorectal cancer varies by setting, with multidisciplinary teams leading coordinated care in academic centers, whereas surgeons in rural or resource-limited areas often take on expanded roles to ensure follow-up and monitoring are not compromised.